Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts
Kousain Kousar, Faiza Naseer, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad
{"title":"Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts","authors":"Kousain Kousar, Faiza Naseer, Maisa S. Abduh, Sadia Anjum, Tahir Ahmad","doi":"10.1186/s12645-024-00279-x","DOIUrl":null,"url":null,"abstract":"<p><b>Retraction</b><b>: </b><b>Cancer Nanotechnology (2023) 14:71 </b><b>https://doi.org/10.1186/s12645-023-00220-8</b></p><p>The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding overlapping images in the presented data. Specifically:</p><p>Multiple images in Fig. 8a appear highly similar to those in Fig. 17 in Naseer et al. (2023), representing different groups.</p><p>Multiple images in Fig. 8b appear highly similar to those in Fig. 18 in Naseer et al. (2023), representing different groups.</p><ul>\n<li>\n<p>Fig. 8a D1 appears highly similar to Fig. 8b D3.</p>\n</li>\n<li>\n<p>Fig. 8a E1 and E2 appear to overlap with different magnification.</p>\n</li>\n<li>\n<p>Fig. 9a A5 insert (low magnification image) appears highly similar to that in B5.</p>\n</li>\n<li>\n<p>Fig. 9a A9 and b D7 appear to overlap with different contrast.</p>\n</li>\n<li>\n<p>Fig. 9a A10, A12 and B10 appear to overlap.</p>\n</li>\n<li>\n<p>Fig. 9a B1 and b C1, C3 appear to overlap with different magnification.</p>\n</li>\n<li>\n<p>Fig. 9a B3 and b C2, D2 appear to overlap with different magnification and contrast.</p>\n</li>\n<li>\n<p>Fig. 9a B4 and b D4 appear to overlap.</p>\n</li>\n<li>\n<p>Fig. 9a B10 and B11 appear to overlap.</p>\n</li>\n</ul><p>Additionally, the rat body weight data presented in Fig. 5a (~ 160 g at week 1) appear to be contrary to the description in the Methods (200–250 g).</p><p>The Editors-in-Chief therefore no longer have confidence in the presented data.</p><p>None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.</p><ul data-track-component=\"outbound reference\" data-track-context=\"references section\"><li><p>Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2</p><p>Article CAS Google Scholar </p></li></ul><p>Download references<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><h3>Authors and Affiliations</h3><ol><li><p>Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan</p><p>Kousain Kousar, Faiza Naseer & Tahir Ahmad</p></li><li><p>Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan</p><p>Faiza Naseer</p></li><li><p>Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia</p><p>Maisa S. Abduh</p></li><li><p>Department of Biology, University of Hail, Hail, Saudi Arabia</p><p>Sadia Anjum</p></li></ol><span>Authors</span><ol><li><span>Kousain Kousar</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Faiza Naseer</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Maisa S. Abduh</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Sadia Anjum</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li><li><span>Tahir Ahmad</span>View author publications<p>You can also search for this author in <span>PubMed<span> </span>Google Scholar</span></p></li></ol><h3>Corresponding authors</h3><p>Correspondence to Kousain Kousar or Tahir Ahmad.</p><h3>Publisher's Note</h3><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p><p><b>Open Access</b> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</p><img alt=\"Check for updates. Verify currency and authenticity via CrossMark\" height=\"81\" loading=\"lazy\" src=\"data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>\" width=\"57\"/><h3>Cite this article</h3><p>Kousar, K., Naseer, F., Abduh, M.S. <i>et al.</i> Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. <i>Cancer Nano</i> <b>15</b>, 40 (2024). https://doi.org/10.1186/s12645-024-00279-x</p><p>Download citation<svg aria-hidden=\"true\" focusable=\"false\" height=\"16\" role=\"img\" width=\"16\"><use xlink:href=\"#icon-eds-i-download-medium\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"></use></svg></p><ul data-test=\"publication-history\"><li><p>Published<span>: </span><span><time datetime=\"2024-07-30\">30 July 2024</time></span></p></li><li><p>DOI</abbr><span>: </span><span>https://doi.org/10.1186/s12645-024-00279-x</span></p></li></ul><h3>Share this article</h3><p>Anyone you share the following link with will be able to read this content:</p><button data-track=\"click\" data-track-action=\"get shareable link\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Get shareable link</button><p>Sorry, a shareable link is not currently available for this article.</p><p data-track=\"click\" data-track-action=\"select share url\" data-track-label=\"button\"></p><button data-track=\"click\" data-track-action=\"copy share url\" data-track-external=\"\" data-track-label=\"button\" type=\"button\">Copy to clipboard</button><p> Provided by the Springer Nature SharedIt content-sharing initiative </p>","PeriodicalId":9408,"journal":{"name":"Cancer Nanotechnology","volume":"154 1","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Nanotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1186/s12645-024-00279-x","RegionNum":2,"RegionCategory":"工程技术","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NANOSCIENCE & NANOTECHNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Retraction: Cancer Nanotechnology (2023) 14:71 https://doi.org/10.1186/s12645-023-00220-8
The Editors-in-Chief have retracted this article. After publication, concerns were raised regarding overlapping images in the presented data. Specifically:
Multiple images in Fig. 8a appear highly similar to those in Fig. 17 in Naseer et al. (2023), representing different groups.
Multiple images in Fig. 8b appear highly similar to those in Fig. 18 in Naseer et al. (2023), representing different groups.
Fig. 8a D1 appears highly similar to Fig. 8b D3.
Fig. 8a E1 and E2 appear to overlap with different magnification.
Fig. 9a A5 insert (low magnification image) appears highly similar to that in B5.
Fig. 9a A9 and b D7 appear to overlap with different contrast.
Fig. 9a A10, A12 and B10 appear to overlap.
Fig. 9a B1 and b C1, C3 appear to overlap with different magnification.
Fig. 9a B3 and b C2, D2 appear to overlap with different magnification and contrast.
Fig. 9a B4 and b D4 appear to overlap.
Fig. 9a B10 and B11 appear to overlap.
Additionally, the rat body weight data presented in Fig. 5a (~ 160 g at week 1) appear to be contrary to the description in the Methods (200–250 g).
The Editors-in-Chief therefore no longer have confidence in the presented data.
None of the authors have responded to any correspondence from the editor or publisher about this retraction notice.
Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation. Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2
Article CAS Google Scholar
Download references
Authors and Affiliations
Industrial Biotechnology, Atta-ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan
Kousain Kousar, Faiza Naseer & Tahir Ahmad
Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad, Pakistan
Faiza Naseer
Immune Responses in Different Diseases Research Group, Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdul-Aziz University, 21589, Jeddah, Saudi Arabia
Maisa S. Abduh
Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi Arabia
Maisa S. Abduh
Department of Biology, University of Hail, Hail, Saudi Arabia
Sadia Anjum
Authors
Kousain KousarView author publications
You can also search for this author in PubMedGoogle Scholar
Faiza NaseerView author publications
You can also search for this author in PubMedGoogle Scholar
Maisa S. AbduhView author publications
You can also search for this author in PubMedGoogle Scholar
Sadia AnjumView author publications
You can also search for this author in PubMedGoogle Scholar
Tahir AhmadView author publications
You can also search for this author in PubMedGoogle Scholar
Corresponding authors
Correspondence to Kousain Kousar or Tahir Ahmad.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Cite this article
Kousar, K., Naseer, F., Abduh, M.S. et al. Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts. Cancer Nano15, 40 (2024). https://doi.org/10.1186/s12645-024-00279-x
Download citation
Published:
DOI: https://doi.org/10.1186/s12645-024-00279-x
Share this article
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
撤稿:Cancer Nanotechnology (2023) 14:71 https://doi.org/10.1186/s12645-023-00220-8The 主编已撤回这篇文章。文章发表后,有人对文中数据中的重叠图像提出了质疑。具体来说:图 8a 中的多幅图像与 Naseer 等人(2023 年)的图 17 中的图像高度相似,代表不同的组别。图 8b 中的多幅图像与 Naseer 等人(2023 年)的图 18 中的图像高度相似,代表不同的组别。图 9a A5 插页(低放大率图像)与 B5 中的插页高度相似。图 9a A9 和 b D7 以不同的对比度出现重叠。此外,图 5a 中显示的大鼠体重数据(第 1 周时约为 160 克)似乎与《方法》中的描述(200-250 克)相反。Naseer F, Kousar K, Abduh MS et al (2023) Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation.Cancer Nanotechnol 14:65. https://doi.org/10.1186/s12645-023-00218-2Article CAS Google Scholar Download references作者及工作单位巴基斯坦伊斯兰堡国立科技大学阿塔-乌尔-拉赫曼应用生物科学学院工业生物技术Kousain Kousar, Faiza Naseer &;Tahir Ahmad巴基斯坦伊斯兰堡希法塔梅尔-伊-米拉特大学希法制药科学学院法伊扎-纳西尔沙特阿拉伯吉达 21589 阿卜杜勒-阿齐兹国王大学应用医学系医学实验室科学系不同疾病中的免疫反应研究小组麦萨-S.AbduhCenter of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah, Saudi ArabiaMaisa S. AbduhDepartment of Biology, University of Hail, Hail, Saudi ArabiaSadia AnjumAuthorsKousain KousarView author publications您也可以在PubMed Google Scholar中搜索该作者Faiza NaseerView author publications您也可以在PubMed Google Scholar中搜索该作者Maisa S. Abduh查看作者发表的论文Abduh查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Sadia Anjum查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者Tahir Ahmad查看作者发表的文章您也可以在PubMed Google Scholar中搜索该作者通信作者Kousain Kousar或Tahir Ahmad.Publisher's NoteSpringer Nature对出版地图和机构隶属关系中的管辖权主张保持中立。开放获取 本文采用知识共享署名 4.0 国际许可协议,该协议允许以任何媒介或格式使用、共享、改编、分发和复制本文,但必须注明原作者和出处,提供知识共享许可协议的链接,并说明是否进行了修改。本文中的图片或其他第三方材料均包含在文章的知识共享许可协议中,除非在材料的署名栏中另有说明。如果材料未包含在文章的知识共享许可协议中,且您打算使用的材料不符合法律规定或超出许可使用范围,您需要直接从版权所有者处获得许可。如需查看该许可的副本,请访问 http://creativecommons.org/licenses/by/4.0/。创意共享公共领域专用免责声明(http://creativecommons.org/publicdomain/zero/1.0/)适用于本文提供的数据,除非在数据的信用行中另有说明。 引用本文Kousar, K., Naseer, F., Abduh, M.S. et al. Retraction Note: Green synthesis of oncolytic Newcastle disease virus-loaded thiolated chitosan nanoformulation for CD44 targeted delivery and sustained release of virus in cervical cancer xenografts.Cancer Nano 15, 40 (2024). https://doi.org/10.1186/s12645-024-00279-xDownload citationPublished: 30 July 2024DOI: https://doi.org/10.1186/s12645-024-00279-xShare this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a shareable link is not currently available for this article.Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative.
Cancer NanotechnologyPharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
5.20
自引率
1.80%
发文量
37
审稿时长
15 weeks
期刊介绍:
Aim:
Recognizing cancer as a group of diseases caused by nanostructural problems (i.e. with DNA) and also that there are unique benefits to approaches inherently involving nanoscale structures and processes to treat the disease, the journal Cancer Nanotechnology aims to disseminate cutting edge research; to promote emerging trends in the use of nanostructures and the induction of nanoscale processes for the prevention, diagnosis, treatment of cancer; and to cover related ancillary areas.
Scope:
Articles describing original research in the use of nanostructures and the induction of nanoscale processes for the prevention, diagnosis and treatment of cancer (open submission process). Review, editorial and tutorial articles picking up on subthemes of emerging importance where nanostructures and the induction of nanoscale processes are used for the prevention, diagnosis and treatment of cancer.